[
    [
        {
            "time": "2023-10-01",
            "original_text": "复星医药(02196.HK)子公司通过GMP符合性检查",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "GMP符合性检查"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)子公司通过GMP符合性检查",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "复星医药(02196.HK)子公司斯鲁利单抗注射液联合重组抗EGFR人源化单克隆抗体注射液用于治疗晚期实体瘤开展II期临床试验获批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "斯鲁利单抗",
                    "重组抗EGFR",
                    "临床试验",
                    "晚期实体瘤"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "肿瘤治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)子公司斯鲁利单抗注射液联合重组抗EGFR人源化单克隆抗体注射液用于治疗晚期实体瘤开展II期临床试验获批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "复星医药(600196.SH)：斯鲁利单抗注射液、重组抗EGFR人源化单克隆抗体注射液获药品临床试验批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "斯鲁利单抗",
                    "重组抗EGFR",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "肿瘤治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：斯鲁利单抗注射液、重组抗EGFR人源化单克隆抗体注射液获药品临床试验批准",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "复星医药(600196.SH)：斯鲁利单抗注射液联合HLX07治疗晚期实体瘤获准开展II期试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "斯鲁利单抗",
                    "HLX07",
                    "晚期实体瘤",
                    "II期试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "肿瘤治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：斯鲁利单抗注射液联合HLX07治疗晚期实体瘤获准开展II期试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "复星医药(600196.SH)子公司二车间硬胶囊生产线通过GMP符合性检查",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "硬胶囊生产线",
                    "GMP符合性检查"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "生产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)子公司二车间硬胶囊生产线通过GMP符合性检查",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "复星医药：子公司获药品临床试验批准",
            "features": {
                "keywords": [
                    "复星医药",
                    "子公司",
                    "临床试验"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药",
                    "研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "复星医药：子公司获药品临床试验批准",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "抢占科创高地，面向全球招才引智!复星亮相首届全国博士后创新创业大赛",
            "features": {
                "keywords": [
                    "复星",
                    "科创高地",
                    "全球招才引智",
                    "博士后大赛"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "创新",
                    "人才引进"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "抢占科创高地，面向全球招才引智!复星亮相首届全国博士后创新创业大赛",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]